BioPorto Diagnostics A/S

We are an in-vitro diagnostics Danish company offering a unique portfolio of immunoassays and lateral flow assay tools, monoclonal antibodies and matched antibody pairs for pharma and clinical research, as well as clinical diagnostics. We develop and produce highly specific antibodies within clinical areas such as Acute Kidney Injury (AKI), Obesity and Diabetes, Innate Immunity, Allergy and Infectious Diseases, and our antibodies are also relevant in the study of the Complement System, Coagulation and Cell Biology, just to name a few. We also have a distinctive set of matched antibody pairs and a generic Lateral Flow Device (gRAD), which allow our users to create new customized immunoassay solutions. In the clinical diagnostics arena, BioPorto Diagnostics A/S has launched The NGAL Test™, a market leading CE IVD* turbidimetric immunoassay for quantitative determination of NGAL, a novel biomarker for the diagnosis of AKI. We are also among the major players in helping diagnosis of Primary Immune Deficiency with our MBL (Mannan-Binding Lectin) ELISA KIT, a CE IVD* test used in routine diagnostics and research of the Complement System. BioPorto Diagnostics A/S also offers a comprehensive set of highly reproducible and easy-to-use ELISA kits for animal and human NGAL, used in pre-clinical and clinical research trials to assess nephrotoxicity at early stages of new drug development. * For diagnostic use in selected countries. See www.bioporto.com for availability in your country.